Aims. The main aims of this paper are: (1) to evaluate the impact of partial breast gland removal, for cosmetic or functional reasons on cancer incidence in the long-term post-surgical follow-up; (2) to define the incidental cancer finding during breast reduction; (3) to examine the oncological perspective of contralateral breast reduction in women with post-mastectomy breast reconstruction, (4) to consider the impact of breast reduction techniques as first choice procedure in the treatment of cancers in megalomastia. Methods. We reviewed the clinical articles published in the last 20 years addressed to the relationship between the amount of tissue removed and cancerogenesis of the remnant gland. The review has been also extended to published papers outlining the future trends of breast reduction procedures from an oncological perspective, potentially as specific choice of selected cancer treatment in megalomastia. Results. Assessment of the literature data reveals that breast reduction does decrease the risk of breast and other types of cancers. The actual risk lowering for patients older than 40 is related to the amount of tissue removed. Conclusion. This study illustrates that breast reduction surgery should be encouraged, besides the known aims, as a preventive operation in those patients presenting degrees of breast hypertrophy and a family history of breast cancer.
Introduction
Breast reduction (BR), or reduction mastoplasty operation is a plastic procedure based on different surgical techniques, aiming at reducing the breast volume when it affects the quality of life.
Cancer may be detected either as an incidental finding during operation or in the long run after surgery.
The subject has been widely investigated in the last 20 years: specifically, the management of unexpected tumours, and the relationship between the amount of tissue removed and cancerogenesis of the remnant gland, with or without a case-control comparison, have been focused.
In this work we shall review the available clinical studies (see Tables 1-4) trying to outline an adequate preintraoperative diagnostic protocol, and to design the future trends of the procedure from the oncological point of view.
Breast reduction and cancer in the long-term follow-up
The first report from Lund et al. [1] (see Table 1 ) describes 1245 women between 20 and 70 years undergone breast reduction in Denmark in the interval 1943-1971 with different surgical procedures. They observed 18 cases of breast cancers and expected 30.28, for a relative risk (R.R., defined as the ratio between observed and expected cancers) of 0.39.
In the first 10 years of follow-up, 5 cases were detected (7.11 expected); after 10 years 13 cases were detected (23.17 expected). The greatest advantage in cancer risk reduction was experienced in women with a removal of 600 g or more tissue (R.R. = 0.31, 95% confidence interval (CI): 0.06-0.91).
Nine years later Baasch et al. [2] , following-up to 1990 the original group of Lund, fixed the relative risk to 0.61, and supported Lund's observation that 600 g weight or more was the critical mass resected to achieve significant cancer risk reduction.
This long follow-up (19 years) on 1240 patients gave 32 observed cancers versus 52.55 expected; the women operated at the age of 20 more less had a substantial but not statistically significant risk of malignancy compared to the general populations or other age groups. In his Copenhagen series, 30% reduction in risk was seen among women aged between 21 and 40 in long-term follow-up (20.7% of the patients 40 years old or older were nulliparous, compared with 20% in the general population, with the number of children equal to 1.7 and mean age 24.0 at the first birth, both similar to the general population). The long-term follow-up did not show any specific trend toward cancerization. The population compliance to X-rays screening for preop- 
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Risk factors (R.R.) Lund (1987) [1] 1245 (20- Brinton (1996) [3] Brown (1999) [6] As to the relationship between cancer incidence and age, it has to be stressed that younger females compared to the old ones are usually more slim with large breasts; older women are often overweight or frankly obese: this might increase the risk of tumourigenesis, and also the protection offered by breast reduction surgery. In fact, not only the glandular mass that potentially is expected to become malignant is reduced, but also a large number of adipocytes in the fat tissue, that are responsible for enhancing hormone co-carcinogenic potential transforming androstenedione into estrogens through aromatase.
A small population based case-control report on BR and cancer, by Brinton et al. [3] was part of an investigation on surgical breast enlargement which included 2174 patients and 2009 controls with previous breast implants but only 10 reductive mammoplasties and 13 controls. In the prosthesis group the observed percentage of cancers 36 cases (1.1%) versus 44 (2%) of the controls showed a risk reduction R.R. of 0.2 and a R.R. of 0.8 for both localized and distant tumours: the risk reduction in reductive mastoplasties was 0.7% (95% CI: 0.4-1.0).
Boice et al. [4] examined the Danish hospital discharge registry of 7720 women that underwent breast reduction between 1977 and 1992, with specific focus on risk by age and time since surgery. The median age at time of surgery was 46 years and the mean follow-up 7.5 years. 182 various type cancers were observed in the follow-up, compared with 209 expected (standardized incidence ratio SIR = 0.9%; 95% CI: 0.7-1.0). Specifically the breast cancers were reduced roughly to 50% (29 observed versus 53.9 expected with R.R. = 0.54). Patients age at surgery was meaningful, being the risk reduced at the age of 40, and subsequently at 50 of an overall 70%.
Jansen et al. [5] , from a retrospective study of 2576 breast reductions reported 4 cases (0.16%) of intraoperative cancer detection, that escaped to routine mammography, self exam and physical examination by the surgeons. This different rate of incidental tumour finding at the reduction surgery time might be explained on the basis of different accuracy in preoperative breast examination. Nearly 660 patients with preexisting breast cancer before the operation were subsequently found not at risk for the contralateral operated breast, exposed to high risk of cancer.
Brown et al. [6] using the Canadian Institute for Health databank identified 30137 women submitted to bilateral (94.7%) or unilateral (5.3%) breast reduction between 1979 and 1992. The final eligible cases were 26,567 bilateral reductions and 933 unilateral reductions. Of this latter group 412 patients had prior breast cancer, 314 had prior or synchronous cancer, and 87 of these (27.7%) had specific breast cancer, with 18 cases detected during the operation. Among the 26,567 operated women an amount of 101 cancers were observed compared with the expected 165.8, yielding a R.R. of 0.61 (95% CI: 0.50-0.74). As to the other primary cancers, there were 285 cases observed and 372.5 expected with R.R. = 0.77 (95% CI: 0.68-0.86).
Lung cancer, cervical carcinoma and noncolorectal gastrointestinal tract tumours were most frequently observed, but they also presented a well defined reduced risk to 0.59, 0.51 and 0.58, respectively. Probably, this benefit was due to post-operative lifestyle changes, such as stop smoking, increasing physical activity and weight reduction.
Evaluating the breast cancer incidence in the first 10 years post-operation, 86 were observed versus 147 expected. The remaining 15 cases occurred 10-14 years after the initial surgery. Thus, the relative risk in the first 10 years was 0.59 (95% CI: 0.47-0.72); for the remaining 4 years it rose up to 0.80 (95% CI: 0.45-1.32). No difference in risk between groups evaluated on decades of age was observed.
Tang et al. [7, 8] reports a cohort study of breast cancer risk in breast reduction patients (27,500 cases and 101 cancers found) following a contemporary Brown report that had shown a 40% reduction in the risk of developing breast cancer after breast reduction. In his retrospective survey, the author describes the diagnosis of cancer between 3 months and 13 years after mammaplasty with a median of 5 years. The median age of the patients when submitted to reduction was 50 years, and their average age at the cancer detection was 55, a significantly younger age if compared with 61 of the average cancer detection in the general population. This difference might be explained in terms of more attention and awareness of the breast reduced women focused on their gland health, with an easier physical and instru- mental exploration of the reduced parenchyma. Histology and distribution were similar to control cases, as well as the surgical and oncological protocols. The survival rate at 5 years was 70% in the reduced breast and 77% in the control group, a not significant difference confirmed also by the overlapping of lower and upper confidence level. Boice et al. [9] investigated the oncologic impact of breast reduction on 31,910 women, excluding cancers occurring before and within 3 months of surgery. The mean age at surgery was 33 years and the mean length of follow-up 7.5 years. 662 cancers were observed and 729 were expected (SIR = 0.91, 95% CI: 0.84-0.98) with a 28% breast cancer reduction (161 detected versus 223 expected, SIR 0.72, 95% CI: 0.61-0.84). Lung cancer was also reduced (SIR = 0.73) as well as melanoma (SIR = 0.72). Corpus uteri cancer (SIR = 1.37), thyroid (SIR = 1.39), other endocrine tumours (SIR = 1.55), parathyroid adenomas (SIR = 1.51) were found increased post-operatively. The inverse association between age at surgery with cancer risk is confirmed also in this study: in fact it was reduced respectively to 24 and 43% between the group 40-49, and the group over 50.
Brinton et al. [10] focused their investigation on the amount of tissue removed during reduction mammoplasty toward breast cancer risk. They examined 137 breast reduction specimens and 422 control patients. Subjects with more than 800 g removed had a 76% decreased risk relative to those that had more than 400 g of tissue removed from either breast, irrespectively of the age at surgery. Probably the weak protection from cancer in patients operated before 40 years should be related to the lower volume of tissue removed due to the minor weight of young women compared with older ones, but also to the genetic impact of cancer early in the life; thus a longer followup would allow to correctly evaluate the life span.
Breast reduction and cancer: incidental findings
The incidental finding of breast cancer during cosmetic or symmetrical reconstructive breast reduction (see Table 3 ), has been reported by some authors, [5, 8, [11] [12] [13] [14] but it has to be stressed adequately in order to achieve a preoperative diagnosis and correct planning of tumour surgery.
Rees et al. [11] some years ago outlined the opportunity of careful macroscopic intraoperative fat and gland examination, with further microscopic inspection to detect unrecognized tumours.
Petit et al. [12] , who operated 440 contralateral breasts for symmetric correction, observed 22 (4.4%) occult undetected cancers in the surgical specimen, which were located in the lower quadrant-central area in 70% of the cases. Their size ranged between 3 and 16 mm, 12 of the tumours were in situ and 10 were ductal infiltrating neoplasms. The author stresses the opportunity of performing this reconstructive procedure, from the oncologic point of view to achieve the symmetry of the breast area, thus preventing further tumour incidence on the other side. Jansen et al. [5] starting from occult breast carcinoma occurring in his surgical practice collected a questionnaire from the 43% of the plastic surgeons in New Orleans area. In 2576 BR patients no carcinomas were detected in the preoperative evaluation (self breast exam, physician exam and preoperative mammography). There were four malignancies in the surgical specimens with a rate of 0.16% of breast carcinoma. This incidental finding is significantly lower than the 0.38% of Syndeman and Lizardo [13] (see Table 2 ). This difference might be due to a better mammographic screening that has 85% sensitivity in detecting carcinomas in all the age groups.
Keleher et al. [14] report from M.D. Anderson Cancer Center, shows that incidental breast cancer was found in 4 patients who underwent BR, three of whom had not preoperative mammogram. All the patients underwent modified radical mastectomy.In order to improve cancer detection at the time of BR surgery, the authors suggest the following guidelines on the basis of the women's age different protocols, accordingly with the American Cancer Society [15] : -For patients between 20 and 39, a doctor breast examination with ultrasounds every 1-3 years is recommended with repeated self breast exam regularly in between. -At 40 years or above early physical breast examination, screening mammography and breast self examination should be performed regularly.
The women who have high risk of developing cancer are furtherly subdivided into four groups: breast cancers and 1 or more ovarian in parents and relatives; incidence of breast cancer in sisters before 50 years old, and various penetrance of ovarian mixed with breast cancer in the family). In these cases annual mammography and medical breast examination every 6 months have to be started 5-10 years before the age of the youngest relative affected. BRCA-1 BRCA-2 mutations can involve multiple genes and thus show different expressions of tumours and their follow-up has to be individualized.
As to the surgical techniques in case of cancer incidental finding extensive dissection has to be performed in order to leave at least 1 cm of tumour free breast tissue. The suspected specimen margins have to be marked with ink for correct pathology orientations.
Different containers for the specimen from each breast quadrant have to be sent to the pathologist, and if the diagnosis of suspected tissues is confirmed, a radical modified mastectomy with node dissection and potentially, reconstruction should be considered. In this case Keleher suggests to approach mastectomy through the keyhole incision of the breast reduction technique removing an block the nipple-areola complex with a final vertical and horizontal scar. If the tumour is multicentric and cannot be safely and completely removed with the previous planned incision, the operation can be converted in a standard mastectomy with a different final scar.
Tang et al. [8] identified 17 women with breast cancer at the time of BR out of 27,500 (incidence 0.06%), patients enrolled with over 13 years and 6 months of follow-up. The average age of this intraoperative cancer group was 49 and all the patients underwent bilateral operations. The follow-up of this specific cohort was operating table and 65% were identified by the pathologist. About 65% were ductal and 35% lobular carcinomas; 29% were lymph node positive. In the control group (105 women) selected from Ontario Canada Cancer Registry Database between 1979 and 1993 the mean age of the patients was 61 years and 86% had ductal carcinoma, 10% lobular and 4% ductal and lobular mixed together; they had 42% lymphnodes metastases. Thirtythree percent of the breast reduction group had partial mastectomy at the time of breast reduction without any further operation; 67% had modified radical mastectomy. In the control groups there were 48 partial mastectomies and 32 radical modified mastectomies. Radiotherapy was performed in 50% of the BR group and 71% of the comparison. Twenty-five percent were treated with chemotherapy and hormonal therapy compared with 60% of the comparison group. The 5-year survival rate for breast cancer was 88% in the breast reduction and 67% in the comparison. The explanation for the high incidence of lobular carcinoma (35% compared with 11% of the control), should be due to the fact that this multicentric tumour is more difficult to detect either clinically or mammographically. Tang suggests that the gold standard treatment of intraoperative detected breast cancer should be mastectomy, because typical breast reduction rotates the quadrants and modifies the anatomy of the area to be treated with radiation, with further risk of tumour seeding. The cancer found during reductive surgery in this report affects younger women with earlier diagnosis and a minor number of involved lynphnodes and better 5-years survival.
Oncological perspective of contralateral breast reduction after mastectomy and reconstruction
Other authors [16] [17] [18] [19] [20] have emphasized the role of reduction mammaplasty (RM) in cancer operated breasts remodelling, either contralaterally, or on the same side of a previous quadrantectomy, which is usually cosmetically quite unpleasant (see Table 3 ). Shestak et al. [16] was the first to suggest the RM in four patients with macromastia or mammary hypertrophy and simultaneous carcinoma of the breast. The operation consisted in keyhole markings and wide mammary gland resection with two inferior pedicle reconstruction, and two resection and transplantation of the nipple with an average specimen weight was 825 g. The follow-up between 7 and 43 months was disease-free, and in the author's opinion, this strategy is very well accepted for cosmetic reasons, but it is also quite effective in terms of radiation target and of easier post-operative self-examination.
Breast reduction as a first choice oncologic procedure
Cothier-Savey et al. [17] suggested RM as a safe procedure for breast cancer instead of quadrantectomy, followed by chemo and radio therapy. She evaluated 70 patients operated between 1983 and 1991 of breast reduction and contralateral mastopexy. The cases were matched as to the age, history, stage and pathology of the tumours, etc.
The 5 years overall survival was 85% with 5% local relapses (detected in an interval of 9-43 months, 21 months on average) and 81% of patients satisfaction. The morbility-mortality rate was not superior to the quadrantectomy, and post-operative treatment was the same. The difference of survival and relapse based on the histology and tumour size led to the observation that of the 36 patients with tumour diameter more than 3 cm, local relapses were 3% and actuarial survival 79%. Among all the patients an actuarial rate of 8.5% of local relapses was globally found at 5 years, next to an average delay of illness appearance of 21 months. In-situ cancers were found in 24.2% of the cases, while the remaining were infiltrant cancers; this last group showed local relapse in 8% of the cases with an actuarial survival of 84% at 5 years. The cosmetic outcome was judged very good in 39% of the cases, fair in 36%, acceptable in 24% and poor in 1%.
The reduction specimens weighed between 120 and 440 g with an average of 350 g, and nipple-areola complex was always evaluated with frozen sections, in order to exclude any cancer infiltration.
Clough et al. [18] described 20 patients with lower quadrant cancers between 1983 and 1993, treated with remodelling mammaplasty with nipple bearing superior pedicle, preceded (9 cases) or followed (11 cases) by radiation. Contralateral breast was rendered symmetrical at the same time. The mean resection weight was 248 g (40-540 g).
Pathologic examination showed always free margins and contralaterally fibrocystic disease in 13 patients and a single case of epithelial proliferation. The only one serious post-operative complication was nipple-areola necrosis that required debridement and full thickness skin graft.
With a mean follow-up of 4.5 years, there was 1 local recurrence and 4 distant metastasis but no difference from oncologic point of view in comparison to similar stage-size cancers.
Smith et al. [19] , between 1996 and 1998 operated 10 bilateral breast reduction for breast malignancy followed by radiation therapy. The average amount of tissue removed was 945 g per breast. Radiotherapy started 4 weeks after surgery with 50 Gy in 25 sessions. Follow-up has been 37 months, without recurrence. Cosmetic outcome was excellent, and in the authors' opinion, in suitable women with large ptotic breasts and cancer the reductive choice should be primarily considered.
Spear et al. [20] describes the RM procedure in three cases conservatively operated and radiated for breast cancer. The reductive procedure was performed 3-16 months after surgery. The technical note in this very select cohort of patients was to prepare wide and short flaps, with very little undermining of the skin to avoid dehiscence and ulceration due to post-attinic fibrosis.
The overall number of cancer treated patients is not large enough to give evidence that this treatment can have a specific role in the breast surgery oncological protocols. These anecdotic reports cautiously emphasize the cosmetic role of reducing technique in supporting the psychological distress of women toward amputation perspective introducing a single bilateral procedure.
Discussion
The problem of breast reduction is really not only cosmetic, but also oncologic in perspective, thus we do have evidence, based on the literature reports, that a critical reduction of the amount of gland and fat tissue significantly lowers, in the long run, the breast cancer incidence in the operated cohort of patients (see Tables 1, 3  and 4) .
Also the symmetric reduction after contralateral modified mastectomy and breast reconstruction is an advisable procedure: in fact the increased risk of the patient due to impending carcinogenic factors exposure is counteracted by gland tissue subtraction.
The Breast reduction technique as specific oncologic procedure in some types of cancer developed in the lower quadrants in hypertrophic glands should be cautiously considered, on the basis of wider and accurate case-control investigations: these preliminary literature reports might be the pilot background for a multicenter surgical trial: the psychological comfort of the patients submitted to such a procedure, and followed by radiotherapy and chemo without cosmetically devastating effects, is a an adequate stimulus, to follow-up on this way.
As to the incidental findings of cancer during breast reduction procedure, we think that with a more accurate screening policy, and with the plastic surgeon sensitization toward careful preoperative planning of physical and instrumental investigation, they should virtually disappear; in fact the unexpected cancer identification is a source of distress to the patient, and creates sudden management problem to the surgeon: the gland specimens, individually for each quadrant, must be anyway submitted to detailed pathologist examination.
If an occult breast carcinoma will be microscopically identified the reductive mastoplasty will mean anyway early and effective oncological strategy.
The breast reduction, when its enlargement has reached symptomatic clinical threshold, should therefore be emphasized not only as a restorative procedure for the patient's fitness and wellness but namely as an effective subtraction of the ageing gland tissue inhibiting potential cancerization.
Many women probably might take the challenge to submit themselves to this procedure, if oncologic prevention ought to be achieved; in the RM operated women, cancer risk reduction has otherwise been observed also, for differently located types of tumours, such as lung or G.I. We ignore if a genetic relationship might exist between breast gland plus fat tissue reduction and cancer growth in general: a role to the changes in lifestyle probably related to improved self-esteem and image, as well as to improvement or disappearance of arthro-muscular pain and discomfort might be a partial reasonable explanation of this phenomenon.
We thus should encourage breast reduction in order to improve the wellness and fitness of selected women but also on an oncological preventive perspective if great amount of breast tissue will be resected, and better imaging of the gland will be obtained in the follow-up.
Thus, the strategy of a more appealing middle-aged woman on the background of specific care to reduce the breast cancer incidence and to perform a more effective instrumental follow-up, probably will be endorsed by a larger cohort patients with megalomastia, or breast hypertrophy, and some evidence of breast cancer in parents or relatives, or in genomic analysis.
